Santhera Pharmaceuticals
SANN.SWDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Idebenone
Friedreich's Ataxia
Vamorolone
Duchenne Muscular Dystrophy
POL6014
Cystic Fibrosis
fipamezole
Parkinson's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Idebenone | Phase 3 | Friedreich's Ataxia | - | - |
Vamorolone | Phase 2 | Duchenne Muscular Dystrophy | - | - |
POL6014 | Phase 2 | Cystic Fibrosis | - | - |
fipamezole | Phase 2 | Parkinson's Disease | - | - |
Frequently asked questions
What is in Santhera Pharmaceuticals's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Santhera Pharmaceuticals's (SANN.SW) pipeline across Phase 3, Phase 2. Its lead program is Idebenone (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Santhera Pharmaceuticals's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Santhera Pharmaceuticals (SANN.SW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SANN.SW biotech catalysts?→
Add SANN.SW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Santhera Pharmaceuticals's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.